

Hypercholesterolemia - Pipeline Review, H2 2020

https://marketpublishers.com/r/H807BC988B3EN.html

Date: November 2020

Pages: 269

Price: US\$ 2,000.00 (Single User License)

ID: H807BC988B3EN

Abstracts

Hypercholesterolemia - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypercholesterolemia - Pipeline Review, H2 2020, provides an overview of the Hypercholesterolemia (Metabolic Disorders) pipeline landscape.

Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. This leads in formation of sticky deposits (called plaque) along the artery walls. Plaque can completely block blood flow through an artery, causing heart attack or stroke. Two forms of the condition exist heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). Risk factors include obese, family history, high blood pressure, smoking and diabetes. Treatment includes statins, bile acid sequestrants, fibric acid derivatives and cholesterol absorption inhibitors

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypercholesterolemia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key



players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 8, 17, 8, 2, 13, 9 and 6 respectively. Similarly, the Universities portfolio in Phase 0, Preclinical and Discovery stages comprises 1, 7 and 1 molecules, respectively.

Hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hypercholesterolemia (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hypercholesterolemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.



The pipeline guide evaluates Hypercholesterolemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hypercholesterolemia (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hypercholesterolemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.



Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contents

Introduction

Hypercholesterolemia- Overview

Hypercholesterolemia- Therapeutics Development

Hypercholesterolemia- Therapeutics Assessment

Hypercholesterolemia- Companies Involved in Therapeutics Development

Hypercholesterolemia- Drug Profiles

Hypercholesterolemia- Dormant Projects

Hypercholesterolemia- Discontinued Products

Hypercholesterolemia- Product Development Milestones

Appendix



List Of Tables

LIST OF TABLES

Number of Products under Development for Hypercholesterolemia, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Hypercholesterolemia - Pipeline by 3SBio Inc, H2 2020

Hypercholesterolemia - Pipeline by AD Pharmaceuticals Co Ltd, H2 2020

Hypercholesterolemia - Pipeline by Akcea Therapeutics Inc, H2 2020

Hypercholesterolemia - Pipeline by Alexion Pharmaceuticals Inc, H2 2020

Hypercholesterolemia - Pipeline by Amgen Inc, H2 2020

Hypercholesterolemia - Pipeline by Amryt Pharma Plc, H2 2020

Hypercholesterolemia - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2020

Hypercholesterolemia - Pipeline by Astellas Pharma Inc, H2 2020

Hypercholesterolemia - Pipeline by AstraZeneca Plc, H2 2020

Hypercholesterolemia - Pipeline by Beijing Mabworks Biotech Co Ltd, H2 2020

Hypercholesterolemia - Pipeline by BioLingus AG, H2 2020

Hypercholesterolemia - Pipeline by CardioPharma Inc, H2 2020

Hypercholesterolemia - Pipeline by Centeer BioTherapeutics Ltd Co, H2 2020

Hypercholesterolemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2020

Hypercholesterolemia - Pipeline by Civi Biopharma Inc, H2 2020

Hypercholesterolemia - Pipeline by Cumberland Pharmaceuticals Inc, H2 2020

Hypercholesterolemia - Pipeline by Daewoong Co Ltd, H2 2020

Hypercholesterolemia - Pipeline by Delivra Corp, H2 2020

Hypercholesterolemia - Pipeline by Dogma Therapeutics Inc, H2 2020

Hypercholesterolemia - Pipeline by Draupnir Bio Aps, H2 2020

Hypercholesterolemia - Pipeline by Eight Plus One Pharmaceutical Co Ltd, H2 2020

Hypercholesterolemia - Pipeline by Golden Biotechnology Corp, H2 2020

Hypercholesterolemia - Pipeline by Gruthan Bioscience LLC, H2 2020

Hypercholesterolemia - Pipeline by Guangzhou Jiayue Pharmaceutical Technology Co Ltd, H2 2020

Hypercholesterolemia - Pipeline by Hingez Therapeutics Inc, H2 2020



Hypercholesterolemia - Pipeline by Innovent Biologics Inc, H2 2020

Hypercholesterolemia - Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, H2 2020

Hypercholesterolemia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2020

Hypercholesterolemia - Pipeline by JW Pharmaceutical Corp, H2 2020

Hypercholesterolemia - Pipeline by Kadmon Corp LLC, H2 2020

Hypercholesterolemia - Pipeline by Kowa Co Ltd, H2 2020

Hypercholesterolemia - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2020

Hypercholesterolemia - Pipeline by LIB Therapeutics LLC, H2 2020

Hypercholesterolemia - Pipeline by Lipigon Pharmaceuticals AB, H2 2020

Hypercholesterolemia - Pipeline by LipimetiX Development Inc, H2 2020

Hypercholesterolemia - Pipeline by Luye Pharma Group Ltd, H2 2020

Hypercholesterolemia - Pipeline by Lyndra Therapeutics Inc., H2 2020

Hypercholesterolemia - Pipeline by Madrigal Pharmaceuticals Inc, H2 2020

Hypercholesterolemia - Pipeline by Medlab Clinical Ltd, H2 2020

Hypercholesterolemia - Dormant Projects, H2 2020

Hypercholesterolemia - Discontinued Products, H2 2020



List Of Figures

LIST OF FIGURES

Number of Products under Development for Hypercholesterolemia, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020



I would like to order

Product name: Hypercholesterolemia - Pipeline Review, H2 2020

Product link: https://marketpublishers.com/r/H807BC988B3EN.html

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/H807BC988B3EN.html